The right treatment for the right person at the right time: how far can stratified medicine take us?
|Starts:||14:00 8 Apr 2014|
|Ends:||15:00 8 Apr 2014|
|What is it:||Seminar|
|Organiser:||Institute of Population Health|
|Who is it for:||Adults, Current University students, University staff|
|Speaker:||Dr Richard Emsley|
Host: Centre for Primary Care, Institute of Population Health
About the event:
The idea that a given treatment will have more benefit for some patients than for others is the underlying foundation of what is termed personalised or stratified medicine. If we can identify who these patients are before the decision to give a treatment is made, it will help prevent other patients being exposed to an unnecessary treatment that is likely to be of little or no benefit. As well as the obvious benefits to individual patients, it will also mean that the NHS and other health care providers can save money on expensive treatment costs by targeting the right treatments to the right patients at the right time.
In this talk we will present the underlying concepts of stratified medicine in terms of benefits and harms. We describe why the underlying treatment mechanism is fundamental to evaluation of targeted treatments and describe a new trial design, the Biomarker Stratified Efficacy and Mechanisms Evaluation (BS-EME) trial. We discuss appropriate study designs for validating targeted treatments, and whether electronic health records such as CPRD can be used to target treatments appropriately. This work is part of the MRC North West Hub for Trials Methodology Research.
Dr Richard Emsley
Role: Lecturer in Biostatistics
Organisation: Institute of Population Health
Travel and Contact Information
Seminar room, 5th floor